Ultragenyx gains on Phase II hypophosphatemia analysis

Ultragenyx Pharmaceuticals Inc. (NASDAQ:RARE) added $13.63 (14%) to $112.65 on Thursday after announcing interim results from a dose-finding Phase II study of KRN23 to treat X-linked hypophosphatemia (XLH). Ultragenyx also said the compound received Fast Track designation last week from FDA to treat XLH.

Eight of 11 evaluable patients had improved Thacher Rickets Severity Scores from baseline. All five patients receiving biweekly doses improved, with a mean improvement of 80%. Three of six patients receiving monthly doses had improvements, with a mean improvement of 38%; two had no change and one worsened. ...